After three years of internal development, Expedition is building a generative AI platform for covalent drug discovery, supported by a $50M initial commitment from Flagship Pioneering Multi-target exploration agreement in prostate cancer initiated under Flagship's strategic partnership with Pfizer Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today unveiled Expedition Medicines™, a […]

(NasdaqGM:AVDL), DUBLIN, Oct. 22, 2025 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the global settlement of all litigation with Jazz Pharmaceuticals Inc. (“Jazz”). Under the primary terms of the settlement agreement, Avadel and Jazz will dismiss their respective lawsuits with prejudice. Furthermore,

Hyperscale Data, Inc.(NYSE American: GPUS), a diversified holding company (“Hyperscale Data” or the “Company”), today announced that on October 21, 2025, the NYSE American LLC (“NYSE American”) notified the Company that the Company had successfully regained compliance with the NYSE American's continued listing standards related to its stockholders' equity set forth in Sections 1003(a)(ii) and

Boston Scientific Corporation (NYSE:BSX) generated net sales of $5.065 billion during the third quarter of 2025, growing 20.3 percent on a reported basis, 19.4 percent on an operational1 basis and 15.3 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders

Valens Semiconductor (NYSE: VLN), a leader in high-performance connectivity, today announced that it will release its third quarter 2025 financial results before the market opens on Wednesday, November 12, 2025. https://mma.prnewswire.com/media/2309625/4474760/Valens_Semiconductor_Logo.jpg Gideon Ben Zvi, Chief Executive Officer, and Guy Nathanzon, Chief Financial Officer, will host a conference call on Wednesday, November 12, 2025, at 8:30

ProsperityBancshares, Inc.® (NYSE: PB) today announced that its Board of Directors declared a quarterly common stock dividend of $0.60 per share for the fourth quarter of 2025, payable January 2, 2026, to shareholders of record as of December 15, 2025. The fourth quarter dividend represents an increase of $0.02 per share, or 3.45%, from the

Avadel Pharmaceuticals and Jazz Pharmaceuticals Reach Global Settlement GlobeNewswire October 22, 2025 DUBLIN, Oct. 22, 2025 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the global settlement of all litigation with Jazz Pharmaceuticals Inc. (“Jazz”). Under the primary terms of the settlement agreement,

— The International Tennis Federation (ITF) has increased Kazakhstan's voting allocation from seven to nine — This places Kazakhstan in the ITF's second-highest membership tier, alongside Italy, Spain, Canada, Switzerland, China and Japan — The decision, supported by 91% of delegates, reflects Kazakhstan's success in tennis development and participation TheKazakhstan Tennis Federation (KTF) announces that

AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) — To deliver faster, smarter patient experiences, PatientSync, a leading patient engagement and contact center platform for healthcare providers, has selected Telnyx, the full-stack conversational AI platform, to power its intelligent call flows and mission critical health Voice AI agents. Healthcare organizations rely on PatientSync to manage millions

PatientSync Selects Telnyx to Power AI-Driven Voice Experiences for Healthcare Enterprises GlobeNewswire October 22, 2025 AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) — To deliver faster, smarter patient experiences, PatientSync, a leading patient engagement and contact center platform for healthcare providers, has selected Telnyx, the full-stack conversational AI platform, to power its intelligent call flows